GlassScriptPhysician profile
Eomba Pungu
NPI 1174047070
$3,765.37
in general payments reported to CMS, 2019-2025
24 companies · $629 in 2025
The $629 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $931 · 2022: $763 · 2023: $686 · 2024: $757 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.30 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $614.68 | 2021-2024 | |
| Lilly USA, LLC | $430.82 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $377.86 | 2021-2025 | Krystexxa, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $328.41 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $275.56 | 2021-2025 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $184.57 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $108.59 | 2021 | |
| Pfizer INC. | $100.31 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.17 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $66.20 | 2021 | |
| Paratek Pharmaceuticals, INC. | $49.77 | 2022-2023 | Nuzyra |
| Vanda Pharmaceuticals INC. | $48.39 | 2022-2023 | Hetlioz, Fanapt |
| Aytu Biopharma, INC. | $47.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.83 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $33.77 | 2022-2023 | Seglentis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.06 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $24.17 | 2023 | Gvoke Hypopen |
| Cequr Corporation | $20.69 | 2024 | Cequr Simplicity |
| Eisai INC. | $17.90 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.98 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.92 | 2021 | |
| Horizon Therapeutics Plc | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eomba Pungu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.